Mapping of anti-SARS-CoV-2 antibodies in individuals vaccinated with Comirnatt (Pfizer/BioNTech) who subsequently developed moderate COVID-19 in Reunion Island
The peptCovIDax project proposed to conduct a first serological mapping of individuals who developed a moderate form of COVID-19 despite having completed a full vaccination regimen with the Comirnaty mRNA vaccine. This study is based on the reactivity of serum antibodies to four synthetic peptides M1, NS2, S1P4, and S2P6 using the ELISASev method.
In Reunion Island, it has been observed that individuals with a complete vaccination regimen developed moderate COVID-19 upon contact with an infected person. The high circulation of the Omicron variant, which differs significantly from other Variants of Concern (VOCs), including the Delta variant, could partly explain these cases of symptomatic SARS-CoV-2 infections among individuals vaccinated with Comirnaty. The peptCovIDax project aimed to characterize the antibodies in individuals who developed a moderate form of COVID-19 despite having completed a full vaccination regimen with the Comirnaty mRNA vaccine. This study was based on the reactivity of serum antibodies to the four synthetic peptides M1, NS2, S1P4, and S2P6 using the ELISA method. Some of the results obtained are presented in the article published in Scientific Reports (12:5999, 2022).
